18,386 Shares in Merit Medical Systems, Inc. $MMSI Bought by Ieq Capital LLC

Key Points

• Ieq Capital acquired 18,386 shares of Merit Medical Systems in the second quarter, worth approximately $1.28 million. Institutional investors collectively own 99.66% of the company, with several major funds recently increasing or initiating positions.
• Analysts maintain a favorable outlook, with eight Buy ratings and four Holds producing a consensus “Moderate Buy” rating and an average price target of $100, above the reported $90.54 opening price.
• Merit Medical exceeded quarterly expectations, reporting $1.19 in EPS versus the $0.96 consensus and revenue of $418.84 million. However, shares trade at a premium valuation, with a P/E ratio above 37, leaving greater sensitivity to disappointing results or guidance.

Ieq Capital LLC acquired a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 18,386 shares of the medical instruments supplier's stock, valued at approximately $1,275,000.

A number of other institutional investors and hedge funds also recently modified their holdings of MMSI. Wellington Management Group LLP lifted its stake in Merit Medical Systems by 377.7% in the third quarter. Wellington Management Group LLP now owns 1,240,509 shares of the medical instruments supplier's stock valued at $103,248,000 after purchasing an additional 980,823 shares during the last quarter. Norges Bank bought a new stake in shares of Merit Medical Systems in the fourth quarter valued at $75,957,000. Bank of New York Mellon Corp purchased a new position in shares of Merit Medical Systems during the 2nd quarter valued at $28,470,000. Iron Triangle Partners LP purchased a new position in shares of Merit Medical Systems during the 4th quarter valued at $33,992,000. Finally, Champlain Investment Partners LLC bought a new position in shares of Merit Medical Systems during the 4th quarter worth $32,359,000. 99.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on MMSI. Bank of America increased their target price on Merit Medical Systems from $92.00 to $97.00 and gave the stock a "neutral" rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. boosted their price objective on Merit Medical Systems from $77.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. Robert W. Baird set a $98.00 price objective on Merit Medical Systems in a report on Friday, July 31st. Barrington Research set a $114.00 target price on Merit Medical Systems in a report on Friday, July 31st. Finally, Raymond James Financial reiterated an "outperform" rating and set a $100.00 price target on shares of Merit Medical Systems in a research report on Friday, July 31st. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Merit Medical Systems has a consensus rating of "Moderate Buy" and an average price target of $100.00.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Zacks Research raised several earnings forecasts. The firm increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. It also lifted estimates for Q2 2027, Q3 2027, Q1 2028, and Q2 2028. The revisions suggest improved confidence in Merit Medical’s longer-term earnings growth.
• Positive Sentiment: Longer-term earnings expectations are moving higher. The revised FY2027 and FY2028 forecasts exceed the current-year consensus estimate of roughly $3.81–$3.84 per share, reinforcing the outlook for continued earnings expansion.
• Neutral Sentiment: Short-interest data appears unusable. The report lists short interest at zero shares and describes the change as “NaN,” with a zero days-to-cover ratio. This does not provide a meaningful signal about short-selling pressure or potential short covering.
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q4 2026 EPS forecast slightly to $0.98 from $0.99. While the change is minor, it offsets some of the broader positive revisions and indicates limited near-term earnings impact.
• Negative Sentiment: Valuation leaves less room for disappointment. Merit Medical’s shares recently traded near their 52-week high, with a P/E ratio above 37 and a PEG ratio above 2. Stronger earnings expectations are supportive, but the premium valuation could weigh on the stock if results or guidance fall short.

Merit Medical Systems Stock Performance

Shares of MMSI opened at $90.54 on Thursday. Merit Medical Systems, Inc. has a one year low of $59.74 and a one year high of $94.75. The company has a 50-day simple moving average of $78.85 and a two-hundred day simple moving average of $72.74. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.20 and a quick ratio of 2.79. The firm has a market capitalization of $5.41 billion, a PE ratio of 37.41, a price-to-earnings-growth ratio of 2.27 and a beta of 0.49.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to analyst estimates of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The business's revenue was up 9.5% on a year-over-year basis. During the same period last year, the business earned $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, analysts anticipate that Merit Medical Systems, Inc. will post 3.84 EPS for the current fiscal year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

Want to see what other hedge funds are holding MMSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source